Day One Biopharmaceuticals (DAWN) Other Gross PP&E Adjustments (2022 - 2025)
Day One Biopharmaceuticals (DAWN) has disclosed Other Gross PP&E Adjustments for 4 consecutive years, with -$8.3 million as the latest value for Q4 2025.
- On a quarterly basis, Other Gross PP&E Adjustments rose 26.29% to -$8.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$8.3 million, a 26.29% increase, with the full-year FY2025 number at -$8.3 million, up 26.29% from a year prior.
- Other Gross PP&E Adjustments was -$8.3 million for Q4 2025 at Day One Biopharmaceuticals, down from -$8.2 million in the prior quarter.
- In the past five years, Other Gross PP&E Adjustments ranged from a high of -$1.2 million in Q1 2022 to a low of -$11.3 million in Q4 2024.
- A 4-year average of -$4.9 million and a median of -$4.0 million in 2024 define the central range for Other Gross PP&E Adjustments.
- Peak YoY movement for Other Gross PP&E Adjustments: tumbled 215.46% in 2023, then rose 26.29% in 2025.
- Day One Biopharmaceuticals' Other Gross PP&E Adjustments stood at -$2.8 million in 2022, then tumbled by 85.69% to -$5.1 million in 2023, then crashed by 120.67% to -$11.3 million in 2024, then grew by 26.29% to -$8.3 million in 2025.
- Per Business Quant, the three most recent readings for DAWN's Other Gross PP&E Adjustments are -$8.3 million (Q4 2025), -$8.2 million (Q3 2025), and -$6.5 million (Q2 2025).